HARBIN, China, March 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China (''PRC''), today announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Policresulen vaginal suppositories.
Policresulen vaginal suppositories are indicated for the treatment of cervical erosion, cervicitis, various vaginal inflammations resulting from bacteria, trichomoniasis or candidiasis, and for pressure ulcers due to vaginal pessary. The active ingredient in Policresulen vaginal suppositories is Policresulen, a topical haemostatic and antiseptic. This new product will be available to consumers around June of 2009.
''We are very pleased to receive SFDA approval in a timely manner, which continues to enable us to benefit from the increasing medical consumption in China tied to new health care reforms and a rising middle class,'' said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. ''We remain confident in our ability to identify drugs that have strong market potential that will enhance our portfolio.''
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang
Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang
Pharmaceutical Company (''Jin Chuang'') the Company manufactures and
distributes o
'/>"/>
| SOURCE China Sky One Medical, Inc. Copyright©2009 PR Newswire. All rights reserved |